Neuphoria Therapeutics Inc. (NEUP) Fair Value 2026

NEUP · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.2 /10

32 fundamental signals · 5 models active

Value Trap Risk

WARN (42/100)

Quick Summary — As of 2026-08-28, Neuphoria Therapeutics Inc. (NEUP) trades at $3.76, versus a $3.81 median fair value across its 5 active models — 1.4% above the current price. QOC: 5.2/10. Value Trap Risk: 42/100 (WARN). 5/13 models active. Within that set, the Bayesian DCF component alone returns $3.80.

Key Facts

Ticker
NEUP
Price
$3.76
Quality Score
5.2/10
Value Trap Risk
42/100
Models Active
5/13
Last Updated
Strength: CUCE Ensemble suggests +5.1% upside with 23% confidence
Risk: Value Trap score of 42 suggests caution despite apparent undervaluation

Is Neuphoria Therapeutics Inc. (NEUP) Undervalued or Overvalued in 2026?

According to CirclFi’s 5-model valuation engine, Neuphoria Therapeutics Inc. (NEUP) appears fairly valued as of : the median of 5 independent fair value estimates is $3.81, within 1.4% of the current price of $3.76. Estimates range from $2.99 to $6.98. NEUP scores 5.2/10 on fundamental quality and 42/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. NEUP’s +1.4% gap is narrower than that market norm, and the Biotechnology sector median is -64.7%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Neuphoria Therapeutics Inc. Stock in 2026? →

What Fair Value Does Each Model Give NEUP?

5 Intrinsic Value Models vs. Current Price ($3.76)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $3.80 +1.0%
Ensemble · Medium Conviction
 $3.95 +5.1%
Unlock the Full Matrix

Access 3 additional models including First Chicago, FTNN Topology, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 5 Models →

Cancel anytime · No contracts · Instant access

What Is NEUP's Fair Value Range?

Spread across 5 independent models · $2.99 to $6.98

CirclFi's 5 active models place Neuphoria Therapeutics Inc. (NEUP) between $2.99 and $6.98 per share, a spread of 104% of the median. The median of that range — $3.81 — is the fair value CirclFi publishes for NEUP, against a current price of $3.76.

Low · First ChicagoHigh · FTNN
$2.99median $3.81$6.98
Where the range comes from
Most bearish modelFirst Chicago$2.99
Most bullish modelFTNN Topology$6.98
Model agreement2 bullish · 1 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for NEUP. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on NEUP, not a CirclFi price target. How each model works →

What Is Neuphoria Therapeutics Inc. (NEUP) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Neuphoria Therapeutics Inc.'s intrinsic value is estimated at a median $3.81, showing conflicting signals at the current price of $3.76. While the median implied return is +1.4%, model disagreement is elevated with a gap of +106.0% between the most bullish and bearish estimates. The most optimistic model, FTNN, places fair value at $6.98 (+85.6%), while First Chicago — the most conservative — estimates $2.99 (-20.4%). This +106.0% gap reflects genuine analytical uncertainty about Neuphoria Therapeutics Inc.'s intrinsic worth.

What Do the Models Say About NEUP?

5 of 13 models are currently active for NEUP. Of these, 4 models suggest upside while 1 model suggests overvaluation. Taken together, their median fair value for NEUP is $3.81 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $3.80 on its own, implying +1.0% upside from the current price. See which stocks rank higher →

How Does NEUP Rank in Biotechnology?

Among 625 Biotechnology stocks, NEUP ranks #272 by Quality of Company score. CirclFi's QOC score of 5.2/10 evaluates 32 fundamental signals. A score of 5.2 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

The Biotechnology sector introduces analytical considerations specific to biotech businesses. For Neuphoria Therapeutics Inc., metrics like clinical trial success rate provide important context that general-purpose valuation models may underweight.

Is NEUP a Value Trap?

CirclFi's Value Trap algorithm assigns NEUP a score of 42/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

5 of 13 models are active for Neuphoria Therapeutics Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Neuphoria Therapeutics Inc. scores 5.2 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +106.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every NEUP valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across NEUP's 5 active models, average confidence is 41%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Neuphoria Therapeutics Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

ALMSAlumis Inc.QOC 5.2ALDXAldeyra Therapeutics, Inc.QOC 5.2IMTXImmatics N.V.QOC 5.2MREOMereo BioPharma Group plcQOC 5.2SABSSAB Biotherapeutics, Inc.QOC 5.2CALCCalciMedica, Inc.QOC 5.1IRONDisc Medicine, Inc.QOC 4.6CNXUConexeu Sciences Inc.QOC 3.4CHRSCoherus Oncology, Inc.QOC 6.3EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: ALMS · ALDX · IMTX · MREO · SABS · CALC · IRON · CNXU · CHRS · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to NEUP?

5 companies across all industries closest to NEUP’s Quality of Company score of 5.2/10.

SCNXScienture Holdings, Inc.QOC 5.2SCLXScilex Holding CompanyQOC 5.2PMHSPolomar Health Services, Inc.QOC 5.2PAPLPineapple Financial Inc.QOC 5.2NVDANVIDIA CorporationQOC 10.0

Read investment analysis: SCNX · SCLX · PMHS · PAPL · NVDA

Where Does NEUP Sit in CirclFi's Biotechnology Rankings?

NEUP is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Neuphoria Therapeutics Inc.’s Valuation?

What is Neuphoria Therapeutics Inc.'s intrinsic value in 2026?

CirclFi puts Neuphoria Therapeutics Inc. (NEUP)'s intrinsic value at $3.81 — the median of 5 independent model estimates as of 2026-08-28, ranging from $2.99 to $6.98. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $3.80 on its own. The Quality of Company score is 5.2/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is NEUP overvalued or undervalued right now?

At $3.76, 4 of 5 active models suggest NEUP may be undervalued, while 1 indicate potential overvaluation. The median of all 5 fair value estimates is $3.81, within 1.4% of the current price of $3.76 — a consensus view that NEUP is fairly valued. The assessment depends on which methodology best fits Neuphoria Therapeutics Inc.'s business model in Biotechnology.

What does a Quality of Company score of 5.2 mean for NEUP?

Neuphoria Therapeutics Inc.'s QOC of 5.2/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on NEUP?

CirclFi analyzes NEUP with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 5 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on NEUP?

Of the 5 models currently active on NEUP, FTNN Topology is the most bullish at $6.98 per share, and First Chicago is the most bearish at $2.99. CirclFi's published fair value for NEUP is the median of that range, $3.81, not either extreme. The gap between the two ends equals 104% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is NEUP a value trap in 2026?

Neuphoria Therapeutics Inc.'s Value Trap score is 42/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries.

Cite this analysis — “According to CirclFi’s 5-model valuation engine, Neuphoria Therapeutics Inc. (NEUP) has a median fair value of $3.81 — within 1.4% of the current price of $3.76 — as of 2026-08-28.” Source: circlfi.com/stock/NEUP/ · Methodology
Primary sources for this NEUP valuation
  • Financial statements: Neuphoria Therapeutics Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001191070) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for NEUP as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 5 mathematical frameworks give you clarity on NEUP.

Unlock All 5 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

3 models hidden for NEUP Unlock All 5 — $39/mo